Connection

Angelo Avogaro to Blood Glucose

Back to Details
This is a "connection" page, showing publications Angelo Avogaro has written about Blood Glucose.
Angelo Avogaro
Connection Strength
0.950
Blood Glucose
  1. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017 04 04; 16(1):42.
    View in: PubMed
    Score: 0.243
  2. Head-to-head comparison of the accuracy of Abbott FreeStyle Libre and Dexcom G5 mobile. Nutr Metab Cardiovasc Dis. 2018 04; 28(4):425-427.
    View in: PubMed
    Score: 0.064
  3. FreeStyle Libre and Dexcom G4 Platinum sensors: Accuracy comparisons during two weeks of home use and use during experimentally induced glucose excursions. Nutr Metab Cardiovasc Dis. 2018 02; 28(2):180-186.
    View in: PubMed
    Score: 0.063
  4. Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes. J Clin Endocrinol Metab. 2017 10 01; 102(10):3674-3682.
    View in: PubMed
    Score: 0.063
  5. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017 08; 60(8):1385-1389.
    View in: PubMed
    Score: 0.061
  6. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2017 Jul; 10(7):763-772.
    View in: PubMed
    Score: 0.061
  7. Reduced circulating stem cells associate with excess fasting and post-load NEFA exposure in healthy adults with normal glucose tolerance. Atherosclerosis. 2017 06; 261:117-123.
    View in: PubMed
    Score: 0.060
  8. Influence of health locus of control and fear of hypoglycaemia on glycaemic control and treatment satisfaction in people with Type 1 diabetes on insulin pump therapy. Diabet Med. 2017 05; 34(5):691-697.
    View in: PubMed
    Score: 0.060
  9. The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography. J Endocrinol Invest. 2017 Jun; 40(6):627-634.
    View in: PubMed
    Score: 0.060
  10. Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown. Nutr Diabetes. 2021 01 05; 11(1):1.
    View in: PubMed
    Score: 0.020
  11. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020 Oct; 168:108374.
    View in: PubMed
    Score: 0.019
  12. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019; 7(1):e000725.
    View in: PubMed
    Score: 0.018
  13. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes Obes Metab. 2019 11; 21(11):2542-2552.
    View in: PubMed
    Score: 0.018
  14. Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2018 10 01; 103(10):3773-3782.
    View in: PubMed
    Score: 0.017
  15. Exposure to insulin degludec during pregnancy: report of a small series and review of the literature. J Endocrinol Invest. 2019 Mar; 42(3):345-349.
    View in: PubMed
    Score: 0.017
  16. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes Obes Metab. 2018 07; 20(7):1781-1786.
    View in: PubMed
    Score: 0.016
  17. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol. 2018 Jun; 55(6):593-601.
    View in: PubMed
    Score: 0.016
  18. Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events. Diabetes Metab. 2018 Sep; 44(4):333-340.
    View in: PubMed
    Score: 0.016
  19. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017 Dec; 27(12):1089-1097.
    View in: PubMed
    Score: 0.016
  20. Cognitive, neurophysiologic and metabolic sequelae of previous hypoglycemic coma revealed by hyperinsulinemic-hypoglycemic clamp in type 1 diabetic patients. Metab Brain Dis. 2017 10; 32(5):1543-1551.
    View in: PubMed
    Score: 0.015
  21. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry. Diabetes Obes Metab. 2017 10; 19(10):1416-1424.
    View in: PubMed
    Score: 0.015
  22. Ketone body metabolism in NIDDM. Effect of sulfonylurea treatment. Diabetes. 1992 Aug; 41(8):968-74.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.